Dataset Information


Advances in the Development of Pharmacological Chaperones for the Mucopolysaccharidoses.

ABSTRACT: The mucopolysaccharidoses (MPS) are a group of 11 lysosomal storage diseases (LSDs) produced by mutations in the enzymes involved in the lysosomal catabolism of glycosaminoglycans. Most of the mutations affecting these enzymes may lead to changes in processing, folding, glycosylation, pH stability, protein aggregation, and defective transport to the lysosomes. It this sense, it has been proposed that the use of small molecules, called pharmacological chaperones (PCs), can restore the folding, trafficking, and biological activity of mutated enzymes. PCs have the advantages of wide tissue distribution, potential oral administration, lower production cost, and fewer issues of immunogenicity than enzyme replacement therapy. In this paper, we will review the advances in the identification and characterization of PCs for the MPS. These molecules have been described for MPS II, IVA, and IVB, showing a mutation-dependent enhancement of the mutated enzymes. Although the results show the potential of this strategy, further studies should focus in the development of disease-specific cellular models that allow a proper screening and evaluation of PCs. In addition, in vivo evaluation, both pre-clinical and clinical, should be performed, before they can become a real therapeutic strategy for the treatment of MPS patients.

SUBMITTER: Losada Diaz JC 

PROVIDER: S-EPMC6981736 | BioStudies | 2019-01-01

REPOSITORIES: biostudies

Similar Datasets

2018-01-01 | S-EPMC5986190 | BioStudies
2020-01-01 | S-EPMC7460463 | BioStudies
2017-01-01 | S-EPMC5500627 | BioStudies
2018-01-01 | S-EPMC6238248 | BioStudies
2020-01-01 | S-EPMC7036933 | BioStudies
2013-01-01 | S-EPMC3662312 | BioStudies
1000-01-01 | S-EPMC6011039 | BioStudies
1000-01-01 | S-EPMC6238257 | BioStudies
2020-01-01 | S-EPMC7139616 | BioStudies
2020-01-01 | S-EPMC7178160 | BioStudies